commd7 Gene Expression in ALL
NCT05592470 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 102
Last updated 2022-10-24
Summary
* study the expression pattern of COMMD7 gene in acute lymphoblastic leukemia.
* investigate correlation between the expression level of COMMD7 gene with other diagnostic parameters and prognosis in ALL .
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-30
- Primary Completion
- 2024-04-30
- Completion
- 2024-11-30
More Related Trials
-
Assesment of JL1 Expression in Acute Leukemia
NCT04554381 ·Status: UNKNOWN ·Phase: PHASE1
-
Molecular Genetic Lesions and Clinical Outcomes in Children With Acute Lymphoblastic Leukemia
NCT00003291 ·Status: COMPLETED
-
Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).
NCT01282593 ·Status: COMPLETED ·Phase: NA
-
Prognostic Value of CD318 in AML at Assiut University Hospital.
NCT04708444 ·Status: UNKNOWN
-
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
NCT00462761 ·Status: COMPLETED ·Phase: PHASE1
-
Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia
NCT04977895 ·Status: RECRUITING
-
Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute Myeloblastic Leukemia (HIFA)
NCT07060612 ·Status: ACTIVE_NOT_RECRUITING
-
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
NCT05875649 ·Status: NOT_YET_RECRUITING
-
Resistance to Methotrexate in Patients With Acute Lymphoblastic Leukemia in Relapse or Remission
NCT00899899 ·Status: COMPLETED
-
Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate
NCT00898404 ·Status: COMPLETED
-
Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells
NCT07236931 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
NCT01034410 ·Status: TERMINATED ·Phase: PHASE2
-
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05673057 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia
NCT07113132 ·Status: NOT_YET_RECRUITING
-
Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid Leukemia
NCT06865443 ·Status: NOT_YET_RECRUITING
-
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
NCT03216070 ·Status: UNKNOWN ·Phase: PHASE4
-
Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia
NCT06469047 ·Status: NOT_YET_RECRUITING
-
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
NCT06055621 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT05703204 ·Status: UNKNOWN ·Phase: PHASE1
-
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
NCT00346632 ·Status: TERMINATED ·Phase: PHASE1
-
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients
NCT03594149 ·Status: COMPLETED ·Phase: PHASE3
-
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy
NCT03889951 ·Status: UNKNOWN
-
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
NCT01685021 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
NCT03060850 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
NCT00079482 ·Status: COMPLETED ·Phase: PHASE2